Melane Sampson, Author at BioTuesdays

Developments

Evogene and BCDD collaborate in drug discovery initiative

Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating...

July 9, 2026

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Developments

First patient dosed in Delcath’s global trial of HEPZATO in mBC

Delcath Systems (NASDAQ: DCTH) has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with...

July 9, 2026

Developments

MAIA reports strong data from trial of 3L therapy in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action...

July 9, 2026

Developments

FDA accepts Organogenesis’ ReNu BLA for knee OA

Organogenesis Holdings (NASDAQ: ORGO) has announced that the FDA has accepted for review its Biologics License Application (BLA) for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of...

July 7, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026

Developments

Alligator highlights first patient dosed in trial of mitazalimab in breast cancer

Alligator Bioscience (STO: ATORX) has announced that the first patient has been dosed in an investigator-led trial evaluating the intratumoral administration of mitazalimab, the company’s lead CD40 agonist, in patients...

July 2, 2026

Executive Moves

Inogen appoints Andy Reding as COO

Inogen (NASDAQ: INGN) has announced the appointment of Andy Reding to the newly created role of chief operating officer (COO), effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue and...

July 2, 2026

Developments

FDA grants Sonoma 510(k) clearance for Microdacyn Wound Irrigation Solution

Sonoma Pharmaceuticals (NASDAQ: SNOA) has received a new 510(k) clearance from the FDA for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging...

June 30, 2026

Executive Moves

Dr. Iain Dukes joins Dogwood as chair of SAB

Dogwood Therapeutics (NASDAQ: DWTX) has announced the appointment of Iain Dukes, PhD, as chair of the company’s scientific advisory board (SAB). Dr. Dukes is a veteran biopharma industry executive and partner with...

June 30, 2026

Author - Melane Sampson

Evogene and BCDD collaborate in drug discovery initiative

CervoMed completes enrollment for study of neflamapimod in nfvPPA

First patient dosed in Delcath’s global trial of HEPZATO in mBC

MAIA reports strong data from trial of 3L therapy in NSCLC

FDA accepts Organogenesis’ ReNu BLA for knee OA

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Alligator highlights first patient dosed in trial of mitazalimab in breast cancer

Inogen appoints Andy Reding as COO

FDA grants Sonoma 510(k) clearance for Microdacyn Wound Irrigation Solution

Dr. Iain Dukes joins Dogwood as chair of SAB

Subscribe